SPRY ARS Pharmaceuticals, Inc.
Price Chart
Executive Summary
ARS Pharmaceuticals appointed Donn Casale as President effective June 1, 2026, replacing CEO Richard Lowenthal who previously held the role. The appointment includes a base salary of $575,000, target bonus of 45%, and a $6M stock option vesting over four years.
Actionable Insight
Routine executive appointment with no immediate impact on operations or financials. Monitor for any strategic shifts under new President; no need for trading action.
Key Facts
- Donn Casale appointed President, effective June 1, 2026, succeeding Richard Lowenthal.
- Annual base salary of $575,000 and target bonus of 45% of base salary.
- Stock option grant valued at approximately $6,000,000 vesting over four years (25% after one year, then monthly).
- Casale previously served as Chief Commercial Officer at Dynavax Technologies (acquired by Sanofi in 2026).
Financial Impact
Compensation package total initial value approximately $6.6M in salary plus option grant; no material financial impact on company.
Risk Factors
- Potential integration risk if Casale's commercial experience does not translate to ARS's product stage.
- No material financial risk from this filing alone.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-220671 |
| Document: d10320d8k.htm | 0001193125-26-220671 |
| Document: 0001193125-26-220671-index-headers.html | 0001193125-26-220671 |
| Document: 0001193125-26-220671-index.html | 0001193125-26-220671 |
| Document: 0001193125-26-220671.txt | 0001193125-26-220671 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 15, 2026
25d ago
|
8-K
| $7.43 $7.94 | ▲ +6.94% | ▲ +5.97% | $8.99 (+21.08%) |
|
May 15, 2026
25d ago
|
Press Release
| $7.43 $7.94 | ▼ −6.94% | ▼ −5.97% | $8.99 (−21.08%) |
|
May 13, 2026
27d ago
|
8-K
| $8.01 $7.17 | ▼ −10.49% | ▼ −9.33% | $8.99 (+12.23%) |
|
May 7, 2026
4w ago
|
Press Release
| $9.00 $8.01 | ▼ −11.00% | ▼ −12.50% | $8.99 (−0.11%) |
|
Mar 27, 2026
10w ago
|
Press Release
| $8.07 $8.39 | ▲ +3.97% | ▲ +0.10% | $8.99 (+11.40%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $9.05 $8.70 | ▼ −3.87% | ▼ −2.51% | $8.99 (−0.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access